Compare Mongodb Inc (MDB) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Merck & Co., Inc. — how do they compare? Mongodb Inc trades at $438 (market cap $33.51B), while Merck & Co., Inc. trades at $130.31 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 9.6× Mongodb Inc's market cap, and Merck & Co., Inc. pays a 2.6% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals.
| MDB | MRK | |
|---|---|---|
Market Cap | $33.51B | $323.00B |
Sector | Technology | Health |
52-Week High | $440.25 | $131.84 |
52-Week Low | $204.37 | $77.60 |
Enterprise Value | $31.12B | $369.77B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $398.8, up 7.78% in the last session, reflecting strong momentum near the consensus price target of $400.39. The stock shows bullish technical signals with support at $384 and resistance at $407. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net margin of -1.12%. Recent quarters have consistently beaten EPS estimates, and analyst sentiment is overwhelmingly positive with 82% buy ratings.
The outlook for MDB is optimistic due to accelerating revenue growth and AI-driven demand, but risks include persistent losses, high valuation multiples, and competitive pressures. Institutional buying and bullish technical trends support near-term upside, yet profitability challenges warrant caution for long-term investors.
MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
